@ Altviolist
I'm now almost down 50% on this position. I even bought a large sum of shares above $11. I never expected this stock would go below $5.
The global ADHD market size is expected to reach USD 24.9 billion by 2025. If we just can get a few percent of the overall market, we'll be ok. The Azstarys patents run until 2037.
@ Phill
I found the Azstarys spreadsheet on Yahoo. I'm not the one updating or making it.
Your correct, the Azstarys deal is worth in regulatory and sales milestones up to $590 million. It's a significant amount.
Kempharm still believes most of it is attainable.
Sales milestones are to be paid based on tiers, unfortunately we don't know the tiers of the agreement.
On top of the sales milestones they get royalties that will be paid from the high single-digits to the mid-twenties in U.S. net sales.
Corium has been apparently waiting for broad payor coverage before a full-launch. The current growth trajectory in scripts makes the potential for earning sales milestones in 2022 attainable.
The buyback program is still in effect:
From December 1, 2021 through December 31, 2021, the Company repurchased 320,161 shares of its common stock for approximately $2.85 million under the Share Repurchase Program.
From January 1, 2022, through March 29, 2022, the Company repurchased 589,792 shares of its common stock for approximately $4.7 million under the Share Repurchase Program.
Total Number of Shares Purchased through March 29, 2022: 909,953 Cost Basis: $ 7,550,000
It’s a tough market environment right now. The XBI is nearly cut in half.
In view of upside potential we have to be patient.